

ForPatients

by Roche

Guillain-Barré Syndrome

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS)

Trial Status
Withdrawn

Trial Runs In
0 Countries

Trial Identifier
NCT05494619 2021-002968-49
BN43118

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of crovalimab compared with placebo as an add-on therapy to intravenous immunoglobulin (IVIg) in participants with severe GBS.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT05494619 2021-002968-49 BN43118
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No
